The potential antifibrotic effects of DPP-4 inhibitors could provide an additional benefit for patients with CKD and heart diseases that very often accompany T2D [35] and may provide new therapy options for this class of drugs. The gene discussed is DPP4; the disease is chronic kidney disease.